Document is current
Any future updates will be listed below
-
Authors
Zhang, Yuening
Wei, Huanhuan https://orcid.org/0000-0001-5741-4114
Nouws, Jessica https://orcid.org/0000-0003-3347-3595
Jiang, Wenhao
Brewster, Reginald M.
Nguyen, Jenny P. https://orcid.org/0000-0003-2952-6877
Liang, SiRu https://orcid.org/0009-0003-7243-9119
Pass, Samuel M.
Wang, Weiwei
Collin, Florine
Oill, Angela Taravella https://orcid.org/0000-0002-4408-7211
Kim, Sang-Hun
Siller, Saul S.
Liu, Jinjiang
Zhao, Amy Y.
Hansbro, Phillip
Dela Cruz, Charles
Britto, Clemente
Gomez, Jose
Cloonan, Suzanne M. https://orcid.org/0000-0001-5301-9926
Herzog, Erica L.
Lam, TuKiet T.
Banovich, Nicholas E. https://orcid.org/0000-0003-2604-3247
Raredon, Micha Sam B. https://orcid.org/0000-0003-1441-6122
Zhang, Xuchen
Mangiola, Stefano https://orcid.org/0000-0001-7474-836X
Homer, Robert J. https://orcid.org/0000-0002-2055-5885
Kaminski, Naftali https://orcid.org/0000-0001-5917-4601
McDonough, John
Polverino, Francesca
Yan, Xiting
Sauler, Maor https://orcid.org/0000-0001-5240-7978
- License Information
-
More Information
Article History
Received: 10 December 2024
Accepted: 11 December 2025
First Online: 23 January 2026
Competing interests
: M.S. has received consulting fees and honorarium from Sanofi-Regeneron and has received grant funding from Genentech. He has a financial interest in Crosswalk Health. N.K. was a consultant to Pliant, AstraZeneca, CSL Behring, Galapagos, GSK, Merck, Thyron and Boehringer Ingelheim over the last 3 years, reports equity in Pliant and received research grants to his laboratory from Veracyte, Boehringer Ingelheim, BMS and AstraZeneca. He has patents on new therapies and biomarkers in pulmonary fibrosis. F.P. has received grants from Victory Houston and Boehringer Ingelheim, and consulting fees from Sanofi-Regeneron, Verona Pharma and Genentech for advisory board participation. The remaining authors declare no competing interests.
